The engines have fired up at last for MDX. ( BPRG ) At long last they are being recognised for the force they will become over the next two years. On the cusp of disclosing huge revenue-earning deals with Global pharmacists. These have been hinted at as being unrolled before the years end, but may be in the next days.You still have time to get in at a bargain-basement price before the SP takes off for real shortly.

They are Dil. More to go into my holding.Glad I 'aint on Spreadbetting with these.

I am not sure what is going on with this company's share price. Some institutional buying and some selling. Overall the buys out way the sales.


I think it has a tremendous potential. I think the methods of delivering some drugs is are evolutionary and proven. It has dropped back from recent highs.



I am not sure what is going on with this company. Some institutional buying and some selling. Overall the buys out way the sales.



The products being brought onto the market and future licences and contracts support a share value in advanced of this price. Directors were buying in September.



I have a feeling the price movements are due to previous punters sitting on good profits and taking them for XMAS and due to past experiences with this company,

Also rebalancing of institutional portfolios.

The products being brought onto the market and future licences and contracts support a share value in advanced of this price. Directors were buying in September.

I have a a "feeling" the price movements are due to previous punters sitting on good profits and taking them for XMAS and due to past experiences with this company.



Have a look at new site http://www.meldexinternational.com/Our_Company/Home.aspx?id=835




Subject: Production & sales stats.
Date: Fri 21st Dec 2007 9:24:20
Country: UK
Industry: Pharmaceuticals & Biotechnology
Company: Meldex International PLC


Meldex International signs new licensing deals, sees more deals in future UPDATE

(Adds further details)
LONDON (Thomson Financial) - Specialty pharmaceutical and healthcare company Meldex International PLC said it has signed new licensing agreements and expects to see further partner discussions announced in 2008.
The company said it has licensed two products that use its Meltums technology and the non-exclusive marketing rights to DBP274, a liquid SoluPol product for the treatment of gastric reflux disease, in certain EU markets.
Meldex said it is currently in talks with the partner to extend territorial rights to DBP274 for further licence payments.
It also said it has completed a licence agreement with another pharmaceutical company for three products for the treatment of dementia and Alzheimer's disease using the Meltums technology and one product for the treatment of obesity, using the TabWrap enabling platform on a global basis.
Meldex said it will retain the global manufacturing rights and will receive significant double-digit royalties when the products are launched in the market.
The company also said it has started the commercialisation of its Collunovar Oradisc product for mouth ulcers. It will be launched under partnership agreements in Eastern Europe and the Middle East.
Meldex said it has received orders for unregulated nicotine products from third-party customers to meet first-quarter 2008 expectations.
The company has also received new orders for sore-throat treatment Hypozalix, with several more licensing deals anticipated in the coming months, and has submitted its analgesic DBP167, which it says has rapid onset of action for pain relief, for UK regulatory approval.
TFN.newsdesk@thomson.com
kal/ajb/kal/kf1

COPYRIGHT

Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.



www.afxpress.com

It's a great shame this site's software doesn't pick-up consolidation - neither does it link old and new names ( rather Epics), unless they are the same ( even if this means two unrelated businesses are linked! )

Something that really should go on a "wish list".

This company changed its name from Bioprogress, for some dubious reasons I fear but that means the chart starts mid-07 . . . whereas it would be nice to relate to their earlier changes.
The last time it aproached 1 (BPRG then), sank to 24p (is that so?) before rallying - indeed I wonder if the name-change wasn't intended to erase that memory.....and a few acquitions dulled the senses that there is little turnover still.
DYOR.

I suspect we'll be seeing 40p's before long as this time of year is not kind and many folks are off-loading their winners and closing Bets, etc.

"Bears in Meldex were sent packing as the junior pharma announced their latest aquisition. But it was not the news of whom the company bought, rather the price of the shares they'd placed to fund the purchase - a near thirty five percent premium to the market price that had traders snapping up the shares on decent volume."

will have a few in the morn me thinks, would imagine thin trading on the market could see a nice rise in these Thurs and Fri.

I won't be in hurry to buy , chart still looks bloody awful.

Charts, farts, this is going to be THE share of 2008. Watch and wonder Dil.

You been saying that for years ... say it often enough and one day you may get it right.

In the meantime until its confirmed that this is the next Microsoft I'm happy to trade it up and down.

Watch and learn kitos.

Yes a good stratergy to use on this company Dil.

Chart certainly points to 42p and maybe lower.

The company have said that they are going to be issuing a strong trading update in Jan.
one of the founders has built up a 7% stake in the company in the last month.
I don't think that this indicates a fall to 42p.

Appears we are on our way back to 97p

Had heard talk about one of the founders buying heavily..........can anyone add to that or is it hearsay?

I thought the founders had got booted out of the company.

Ive heard the management are looking into a naked shorting scandal set up here.

Its certainly listed on the berlin stock exchange.

RNS Credit Agricole reduce shareholding is something going on?

They going short too then GF ?

:-)

wishbone Barry Muncaster has bought over 7% through his company Acquistek in the last month.
the company says they will be issuing a strong trading statement in jan.

all this is on rns so no ramping here.

goldfinger et al hasn't responded to any of this but talk of shorting and getting the price lower.

GB ... you don't really expect any positve comments to have a decent response do you?. But as you say, it's all in black and white, and THAT is indisputable.

Thanks for that Greedybas.

ooooo slap me wrist

The show goes on for Meldex
Created:

31 December 2007

Updated:

2 January 2008

Written by:

Richard Hemming

Meldex's wild run continues. Trading at 60p, its shares have fallen over 30 per cent from a high of 94p on 10 December. But it has been business as usual at the speciality pharmaceutical provider.

It has announced licence agreements for three products and an increase in demand for its unregulated anti-smoking product. It has also acquired three antibiotic products for 14.5m (10.6m), financed by a combination of paper and cash.


--------------------------------------------------------------------------------

IC View
Buy
Despite the share price fall, the Meldex story remains on track. The company has strong earnings growth and Nomura Code's valuation of 115p is almost double the current share price. At 60p, the shares are a buy.